Skip to main content

Table 2 Hypoxia-targeted clinical trials in pancreatic cancer

From: Targeting hypoxic tumor microenvironment in pancreatic cancer

Categories Interventions Pancreatic Cancer Types Phases Status NCT Number
Vascular normalizing agent OXY111A (ITPP) Pancreatic Neoplasms I, II N/A NCT02528526
Chemoradiotherapy (CRT) (nab-paclitaxel, Capecitabine, Gemcitabine, high/low dose of radiation) ± Nelfinavir Pancreatic Neoplasms (Locally Advanced Non-metastatic) I, II Recruiting NCT02024009
Cediranib/Cediranib Maleate + Olaparib Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Unresectable Pancreatic Carcinoma II Recruiting NCT02498613
Antiangiogenic agent Bevacizumab (Anti-VEGF monoclonal antibody) + Capecitabine + Radiation Locally Advanced Pancreatic Cancer I Completed NCT00047710
Sorafenib + Gemcitabine Pancreatic Cancer, Adenocarcinoma of the Pancreas I Completed NCT00375310
Hypoxia-activated prodrug TH-302 (Evofosfamide) + Gemcitabine/ Docetaxel/Pemetrexed Pancreatic Cancer I, II Completed NCT00743379
Gemcitabine + TH-302/Placebo Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma III Completed NCT01746979
TH-302 + Sunitinib Pancreatic Neuroendocrine Tumors I N/A NCT01381822
TH-302 + Ipilimumab Metastatic Pancreatic Cancer I N/A NCT03098160
Inhibition of HIF-1α Digoxin + FOLFIRINOX (5-Fluorouracil, Calcium Leucovorin, Irinotecan, Oxaliplatin) Pancreas Cancer; Adenocarcinoma of the Pancreas II Not yet recruiting NCT04141995
Photodynamic therapy EF5 (a surrogate marker for hypoxia) + Motexafin Lutetium (photosensitizing drug) Recurrent and Stage I to IV Pancreatic Cancer N/A Terminated NCT00087191
  1. The italics in the “Interventions” column represent drugs used for hypoxia-based therapeutic strategies. N/A, not available